larotrectinib(Vitrakvi, BAY2757556)

DRUG2 trials

Sponsors

Bayer

Conditions

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionSolid Tumors Harboring NTRK Fusion

Unknown Phase

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

RecruitingNCT04142437

BayerLocally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

Start: 2020-04-03End: 2030-03-31Target: 150Updated: 2026-07-07

A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

CompletedNCT05192642

BayerSolid Tumors Harboring NTRK Fusion

Start: 2021-12-03End: 2023-08-31Updated: 2023-11-14

Related Papers

Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study.

Journal of Clinical Oncology2024-06-014 citations

CTNI-74. ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION SOLID TUMORS

Neuro-Oncology2023-11-01

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.

2022-06-077 citations

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

The Oncologist2022-04-1445 citations